Future oncology | 2021
Evolving role of entrectinib in treatment of NTRK-positive tumors.
Abstract
Targeted therapy has shown to be a very effective treatment in tumors with specific genomic drivers. Trk\xa0has proven to be one such target. Efforts to target the Trk fusion with specific inhibitors have shown remarkable responses in a tumor agnostic fashion, with responses seen even in patients with intracranial metastasis. Entrectinib is a first-generation Trk inhibitor with impressive activity in early phase trials performed in patients with NTRK fusion positive solid tumors and ROS1 positive non-small-cell lung cancers with subsequent approval for those indications. Entrectinib was also found to be effective in treatment of brain metastasis and generally well tolerated.